ID   1A9PTX15
AC   CVCL_H622
SY   PTX15
DR   cancercelllines; CVCL_H622
DR   Wikidata; Q54582754
RX   PubMed=10871860;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H619 ! A2780-1A9
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 05-10-23; Version: 16
//
RX   PubMed=10871860; DOI=10.1038/sj.onc.1203642;
RA   Giannakakou P., Poy G., Zhan Z.-R., Knutsen T., Blagosklonny M.V.,
RA   Fojo T.;
RT   "Paclitaxel selects for mutant or pseudo-null p53 in drug resistance
RT   associated with tubulin mutations in human cancer.";
RL   Oncogene 19:3078-3085(2000).
//